Long-term Pain Modulation by Intravenous Esketamine in CRPS

NAEnrolling by invitationINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 19, 2022

Primary Completion Date

October 1, 2026

Study Completion Date

October 1, 2027

Conditions
Complex Regional Pain SyndromesCRPS (Complex Regional Pain Syndromes)
Interventions
DRUG

S-ketamine infusion inpatient setting

S-ketamine is administered intravenously for six consecutive days. The administered dose of S-ketamine is 50 mcg/kg/h and can be increased to a maximum of 200 mcg/kg/h.

DRUG

S-ketamine infusion outpatient setting

S-ketamine is administered intravenously for six hours. The administered dose of S-ketamine is 50 mcg/kg/h and can be increased to a maximum of 200 mcg/kg/h.

Trial Locations (1)

3000 CA

Erasmus MC, Rotterdam

Sponsors
All Listed Sponsors
lead

Erasmus Medical Center

OTHER

NCT05212571 - Long-term Pain Modulation by Intravenous Esketamine in CRPS | Biotech Hunter | Biotech Hunter